PMID- 36782214
OWN - NLM
STAT- MEDLINE
DCOM- 20230215
LR  - 20230217
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 18
IP  - 1
DP  - 2023 Feb 13
TI  - Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee 
      osteoarthritis: a systematic review and meta-analysis of randomized controlled 
      trials.
PG  - 100
LID - 10.1186/s13018-023-03590-2 [doi]
LID - 100
AB  - OBJECTIVE: We aimed to evaluate the efficacy and safety of anti-interleukin-1 
      therapeutics, including IL-1 antibodies, interleukin-1 receptor antagonists (IL-1 
      Ras) and IL-1 inhibitors, for knee osteoarthritis (KOA) treatment. METHODS: 
      Databases (Medline, Embase, Web of Science and CENTRAL) and ClinicalTrials.gov 
      were systematically searched for randomized controlled trials (RCTs) of 
      anti-interleukin-1 therapeutics from inception to August 31, 2022. The outcomes 
      were the mean change in pain and function scores and the risk of adverse effects 
      (AEs). RESULTS: In the 12 studies included, anti-interleukin-1 therapeutics were 
      superior to placebo in terms of pain relief (standardized mean difference 
      [SMD] =  - 0.38, 95% confidence interval [CI] =  - 1.82 to - 0.40, p < 0.001, 
      I(2) = 77%) and functional improvement (SMD =  - 1.11, 95% CI =  - 1.82 
      to - 0.40, p = 0.002, I(2) = 96%). The incidence of any AE (risk ratio 
      [RR] = 1.02, 95% CI = 0.88-1.18, p < 0.001, I2 = 76%) was higher following 
      treatment with anti-interleukin-1 therapeutics than placebo, while no significant 
      difference was found in the incidence of serious AEs (SAEs) or discontinuations 
      due to AEs. Subgroup analyses showed that IL-1 antibodies and the IL-1 inhibitor 
      provided pain relief (IL-1 antibodies: SMD =  - 0.61, 95% CI =  - 0.92 to - 0.31, 
      p < 0.001; IL-1 inhibitor: SMD =  - 0.39, 95% CI =  - 0.72 to - 0.06, p = 0.02, 
      I2 = 74.0%) and functional improvement (IL-1 antibodies: SMD =  - 1.75, 95% 
      CI =  - 2.10 to - 1.40, p < 0.001; IL-1 inhibitor: SMD =  - 0.28, 95% 
      CI =  - 0.83 to 0.27, p = 0.31, I(2) = 88%) superior to those of placebo, whereas 
      IL-1 Ras did not. However, the IL-1 inhibitor increased the incidence of any AE 
      (RR = 1.35, 95% CI = 0.92-1.98, p < 0.001, I(2) = 85%) but not the risk of SAEs 
      or discontinuations due to AEs. IL-1 antibodies and IL-1 Ras showed no difference 
      in safety compared with placebo. CONCLUSIONS: Anti-interleukin-1 therapeutics 
      could relieve OA-related pain and improve function, but is probably associated 
      with an increased risk of adverse events. Specially, IL-1 antibodies and an IL-1 
      inhibitor could relieve OA-related pain and improve function, whereas IL-1 Ras 
      could not. IL-1 antibodies and IL-1 Ras were relatively safe options, but IL-1 
      inhibitors were associated with safety concerns.
CI  - (c) 2023. The Author(s).
FAU - Yu, Lizhi
AU  - Yu L
AD  - The First Affiliated Hospital of Guangxi University of Science and Technology, 
      Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, 
      Guangxi Province, China.
FAU - Luo, Raoshan
AU  - Luo R
AD  - The First Affiliated Hospital of Guangxi University of Science and Technology, 
      Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, 
      Guangxi Province, China.
FAU - Qin, Gang
AU  - Qin G
AD  - The First Affiliated Hospital of Guangxi University of Science and Technology, 
      Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, 
      Guangxi Province, China.
FAU - Zhang, Qinyan
AU  - Zhang Q
AD  - The First Affiliated Hospital of Guangxi University of Science and Technology, 
      Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, 
      Guangxi Province, China.
FAU - Liang, Weiming
AU  - Liang W
AD  - The First Affiliated Hospital of Guangxi University of Science and Technology, 
      Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, 
      Guangxi Province, China. liangwm22@icloud.com.
LA  - eng
GR  - Z20190410/the Scientific Research Foundation of Guangxi Health Commission/
GR  - Z20211376/the Scientific Research Foundation of Guangxi Health Commission/
GR  - AD19245017/the Guangxi Natural Science Foundation/
GR  - 20Z13/the Scientific Research Foundation of Guangxi University of Science and 
      Technology/
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230213
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - 0 (Antibodies)
SB  - IM
MH  - Humans
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Pain Management
MH  - Remission Induction
MH  - Antibodies
MH  - Pain
PMC - PMC9923921
OTO - NOTNLM
OT  - Anti-interleukin-1 therapeutics
OT  - IL-1 antibodies
OT  - IL-1 inhibitors
OT  - Interleukin-1 receptor antagonist
OT  - Meta-analysis
COIS- The authors declare that they have no competing interests.
EDAT- 2023/02/15 06:00
MHDA- 2023/02/16 06:00
PMCR- 2023/02/13
CRDT- 2023/02/14 00:13
PHST- 2022/10/22 00:00 [received]
PHST- 2023/02/07 00:00 [accepted]
PHST- 2023/02/14 00:13 [entrez]
PHST- 2023/02/15 06:00 [pubmed]
PHST- 2023/02/16 06:00 [medline]
PHST- 2023/02/13 00:00 [pmc-release]
AID - 10.1186/s13018-023-03590-2 [pii]
AID - 3590 [pii]
AID - 10.1186/s13018-023-03590-2 [doi]
PST - epublish
SO  - J Orthop Surg Res. 2023 Feb 13;18(1):100. doi: 10.1186/s13018-023-03590-2.